Afatinib treatment

DRUG2 trials

Sponsors

Ryo Toyozawa, Sheba Medical Center

Conditions

EGFR mutation-positive non-squamous non-small cell lung cancerNSCLC

Phase 2

An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

Sheba Medical CenterNSCLC

Start: 2013-02-28Target: 20Updated: 2013-08-30

Unknown Phase

Afatinib translational study in patients with EGFR mutation-positive non-squamous non-small cell lung cancer acquired resistance to osimertinib

Active, not recruitingJPRN-jRCTs071180013

Ryo ToyozawaEGFR mutation-positive non-squamous non-small cell lung cancer

Start: 2019-08-16Target: 30Updated: 2026-06-29

Related Papers

A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance.

Journal of Clinical Oncology2015-05-202 citations